Bausch Health Companies (TSE:BHC) Upgraded at Jefferies Financial Group

Jefferies Financial Group upgraded shares of Bausch Health Companies (TSE:BHC) to a hold rating in a research report report published on Wednesday morning,Zacks.com reports.

Bausch Health Companies Stock Down 0.5%

Bausch Health Companies stock opened at C$6.25 on Wednesday. Bausch Health Companies has a 12 month low of C$6.10 and a 12 month high of C$11.97. The stock has a fifty day simple moving average of C$7.02 and a two-hundred day simple moving average of C$7.68. The company has a current ratio of 1.32, a quick ratio of 0.58 and a debt-to-equity ratio of -1,009.96. The firm has a market cap of C$2.33 billion, a price-to-earnings ratio of -1.93, a PEG ratio of 0.21 and a beta of 0.97.

Bausch Health Companies (TSE:BHC) last announced its quarterly earnings results on Wednesday, April 29th. The company reported C$1.08 earnings per share (EPS) for the quarter. Bausch Health Companies had a positive return on equity of 120.43% and a negative net margin of 13.54%.The firm had revenue of C$3.51 billion for the quarter. Equities analysts predict that Bausch Health Companies will post 5.5472637 EPS for the current fiscal year.

About Bausch Health Companies

Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.